 SYMBOTIC COMPOSITIONS FOR RESTORATION AND RECONSTITUTION OF THE INTESTINAL MICROBIOTA
专利摘要:
SYMBOTIC COMPOSITIONS FOR RESTORATION AND RECONSTITUTION OF THE INTESTINAL MICROBIOTA. The present invention relates to symbiotic compositions comprising probiotic bacterial strains and prebiotic substances which, when combined, exhibit synergistic behavior. Synergistic compositions with indigenous microflora to restore and reconstitute intestinal conditions in vivo after antibiotic-associated diarrhea (AAD), and / or other intestinal infections caused by gastrointestinal pathogens, and relapses thereof, as well as the prevention of said disorders. 公开号:BR112013020312B1 申请号:R112013020312-9 申请日:2012-02-09 公开日:2021-03-23 发明作者:Torkel Wadström；Asa Ljungh；Padma Ambalam；Kanthi Kiran Kondepudi 申请人:Synbiotics Ab； IPC主号:
专利说明:
[0001] The present invention relates to symbiotic compositions comprising probiotic bacterial strains and prebiotic substances which, when combined, exhibit synergistic behavior. The synergistic compositions will stimulate the indigenous microflora to restore and reconstitute conditions such as intestinal in vivo after antibiotic-associated diarrhea (AAD), and / or other intestinal infections caused by gastrointestinal pathogens, and their relapse, as well as the prevention of said disorders. BACKGROUND OF THE INVENTION [0002] The intestinal microbiota is a true "extracorporeal organ" with an important role for the body's intrinsic metabolism and various immune functions. This "organ" performs unique digestive functions that simply cannot be achieved by the gastrointestinal tract (GI) of a germ-free animal. However, together the GI and the microbiota form a complex metabolic crosstalk between bacterial species and the host. [0003] Normally, the intestinal mucus layer protects the epithelium against invasion, and colonization by pathogens, and serves as a matrix in which antimicrobial factors produced by the epithelium reside together with strains of the normal intestinal microbiota. This mucus layer constitutes a buffer zone that reaches the luminal compartmentalization of the microbiota and establishes a line of communication for an exchange of molecules through diaphonies between bacterial strains and the intestinal epithelium (Sansonetti, Mucosal Immunol, 2011, 4: 8-14 ). [0004] An increasing use of antibiotics in human and animal medicine actually leads to a severe amplification of antibiotic-resistant strains in the intestine such as methicillin-resistant Staphylococci (MRSA and MRSE), Enterobacteriaceae that produce extended-spectrum β-lactamase (ESBL), Enterococcus vancomycin-resistant spp (VRE), clarithromycin-resistant Helicobacter pilori, vancomycin-resistant Clostridium difficile, quinolone-resistant Campylobacter jejuni and several strains of Candida species. [0005] CD is in small quantities part of the normal indigenous intestinal flora, but broad-spectrum antibiotics such as clindamycin, cephalosporins, and fluoroquinolones, which destroy the indigenous human intestinal microflora, will cause overgrowth in the intestine of CD that produces toxins, destroying enterocytes in the mucosa , and induce diarrhea, which in severe cases leads to pseudomembranous colitis with a high mortality. The CD NAP1 / 027 epidemic strain produces substantially more toxin A and toxin B than hospital strains hitherto isolated and is highly virulent. [0006] The intestinal microbiota is a complex ecosystem that acts in symbiosis with the host. Enteric bifidobacteria (Bif) species have a very high number of genes for metabolizing carbohydrates in the colon whereas lactobacilli are the dominant lactic acid bacteria (LAB) in the small intestine. [0007] Prebiotic fermentation produces short-chain fatty acids (SCFA), such as acetic acid, butyric acid and lactic acid, which reduce the local pH of the colon. In addition, prebiotics and dietary fibers help in the multiplication of LAB and bifidobacteria to produce high cell densities and prevent the growth of said intestinal pathogens mentioned above by producing bactericidal substances, antioxidants, reducing inflammation of the mucosa, maintaining the integrity of mucosal colonies, and promoting strong anti-inflammatory responses from the host. Competitive exclusion is another mode of antimicrobial defense against invading pathogens. [0008] The current use of the terms probiotic and prebiotic is usually related to a complementary symbiotic concept, in which the probiotic is selected based on specific beneficial effects desirable for the host, and the prebiotic is selected to stimulate the growth of indigenous microflora. However, the present invention uses the approach of a new synergistic concept, in which the prebiotic is selected to stimulate the growth of probiotic strains that have specific beneficial effects on the host. It can also increase the levels of beneficial microbiota of the host's GI, but the primary target is to stimulate the growth of ingested probiotic strains. co-cultivation encourages other partners in the composition that are poor to use prebiotic oligosaccharides and other nondigestible carbohydrates in the human intestine. SUMMARY OF THE INVENTION [0009] - pelo menos uma das cepas bacterianas é capaz de degradar amido; e - pelo menos uma substância prebiótica é amido. A first aspect of the invention concerns a symbiotic composition comprising at least two bacterial strains selected from the group consisting of the genera Lactobacillus and Bifidobacteria, and one or more prebiotic substances, characterized by the fact that - at least one of the bacterial strains is capable of degrading starch; and - at least one prebiotic substance is starch. [0010] Advantageously, the bacterial strain capable of degrading starch is of the genus Bifidobacteria, or of the species Bifidobacterium breve such as Bif LU 10. [0011] Advantageously, the starch is resistant starch (RS) and / or soluble starch (SS). [0012] Advantageously, one of said bacterial strains is a strain that does not degrade starch, or of the Lactobacillus paracasei species, such as LAB LU 33. [0013] Advantageously the symbiotic composition comprises at least Bif LU 10 and one or more of the strains LAB LU 23, LAB LU 28, LAB LU 33, BIF LU 29, and / or BIF LU 30, or at least Bif LU 10, and LAB LU 33 , or at least BIF LU 10, LAB LU 33, and BIF LU 30, or at least BIF LU 10, LAB LU 33, BIF LU 30, and LAB LU 28. [0014] Advantageously one or more of the bacterial strains was exposed to acid, bile and / or mucin during their production, such that exposure to acid involves reducing the pH of a culture broth to pH 2-5, preferably up to pH 2.5- 4.5, more preferably pH at 3-4, for 15-150 min, preferably for 20-140 min, more preferably for 30-130 min, more preferably for 40-120 min during the growth of bacterial strains, and exposure bile involves growing bacterial strains in the presence of 0.1-2.5% (w / vol), preferably 0.5-2%, more preferably 1.0-1.5% sodium taurocholate, or 1-10 % (vol / vol), preferably 2-7%, more preferably 3-5% porcine bile for 2-8 h, preferably for 2.5-7 h, more preferably for 3-6 h, and exposure to mucin involves grow bacterial strains in the presence of 0.01-1% (vol / vol), preferably 0.03-0.7%, more preferably 0.05-0.5% mucin for 2-8 h, preferably for 2, 5-7 h, more preferably for 3-6 h. [0015] Advantageously, the symbiotic composition further comprises a prebiotic substance from the group consisting of disaccharides, oligosaccharides, and / or polysaccharides, in which the disaccharide is lactulose, the oligosaccharides belong to the group consisting of fructo-oligosaccharides (FOS), galactooligosaccharides (GOS), X oligosaccharides (XOS), chitosan oligosaccharides (kioses), isomaltose oligosaccharides (IMOS), gum arabic, soy and pectin oligosaccharides, and the polysaccharides are in the group consisting of pectin, xylan, inulin, chitosan, and / or β-glucan . [0016] Advantageously, the symbiotic composition further comprises prebiotic substances from the group consisting of galactooligosaccharides (GOS), Xylooligosaccharides (XOS), isomaltose oligosaccharides (IMOS), fructo-oligosaccharides (FOS) and / or lactulose. [0017] Advantageously, the symbiotic composition also comprises galactooligosaccharides (GOS), and / or Isomaltooligosaccharides (IMOS). [0018] The symbiotic composition as described above is advantageously used in colonizing a subject's intestinal mucosa, and in preventing, treating, improving symptoms, and / or preventing relapse of antibiotic-associated diarrhea (AAD) and / or infections caused by pathogens gastrointestinal disorders in a subject. [0019] Antibiotic-associated diarrhea (AAD) is induced by Clostridium difficile. [0020] Infection with gastrointestinal pathogens is caused by Salmonella, Campylobacter jejuni, E. coli which produces Beta Lactamase of Extended Spectrum (ESBL). [0021] Advantageously the subject is a mammal, such as a mammal of the group consisting of humans, non-human primates, cattle, sheep, pigs, goats and horses, dogs, cats, rodents and guinea pigs. Preferably the subject is a human being. [0022] The symbiotic composition as described above can be used in the manufacture of a medicament for use in colonizing a subject's intestinal mucosa to prevent, treat, ameliorate symptoms of, and prevent relapse of antibiotic-associated diarrhea (AAD), and / or infections caused by gastrointestinal pathogens. [0023] The symbiotic composition as described above can be used to manufacture a drug for use in the treatment of a subject suffering from antibiotic-associated diarrhea (AAD), and / or infections caused by gastrointestinal pathogens. [0024] The symbiotic composition as described above can be used in a method for colonizing a subject's intestinal mucosa, said method comprising the step of administering the symbiotic composition in an effective dose to a subject in need thereof. [0025] The symbiotic composition as described above can be used in a method to treat a subject of antibiotic-associated diarrhea (AAD) and / or infections caused by gastrointestinal pathogens, said method comprising the step of administering the symbiotic composition in an effective dose to a subject in need of it. DEFINITIONS [0026] The terms used in this invention are generally expected to adhere to standard definitions accepted by those who have ordinary skill in the technique of microbiology and biochemistry. A few exceptions, as listed below, have been further defined within the scope of the present invention. [0027] As used in this document, the term "disaccharide" is the carbohydrate formed when two monosaccharides undergo a condensation reaction that involves the elimination of a small molecule, such as water, from the functional groups only. [0028] As used in this document, the term "oligosaccharide" refers to a polymer of saccharides containing a small number of sugars (monosaccharides), usually two to ten. [0029] As used in this document, the term "polysaccharides" are polymeric carbohydrate structures formed from repeated units (mono- or disaccharides) joined together by glycosidic bonds. These structures are often linear, but can contain varying degrees of branching. [0030] As used herein, the term "starch" is a carbohydrate consisting of a large number of glucose units joined together by glycosidic bonds. This polysaccharide is produced by all green plants as an energy store. It consists of two types of molecules: linear and helical amylose and branched amylopectin. Depending on the plant, starch usually contains 20 to 25% amylose and 75 to 80% amylopectin. The term starch includes, but is not limited to, soluble starch (SS), resistant starch (RS) of cereals (rice, wheat, and corn), root vegetables (potatoes and cassava), acorns, arrowroot, arracacia, bananas, barley, breadfruit, buckwheat, beacon, colacásia, katakuri, kudzu, malanga, millet, oats, hollow, Polynesian arrowroot, sago, sorghum, sweet potatoes, rye, taro, chestnuts, water chestnuts and yams, beans, such as broad beans, lentils, mung beans, peas, and chickpeas. [0031] As used in this document, the term "probiotics" refers to bacteria that, when consumed in sufficient quantities, confer a health benefit. [0032] As used herein, the term "prebiotics" refers to substances that are nondigestible food ingredients that stimulate the growth and / or activity of bacteria in the digestive system in the ways claimed to be beneficial to health. [0033] As used in this document, the term "symbiotics" refers to nutritional supplements or medication to combine probiotics and prebiotics in a form of synergism. A symbiotic composition will stimulate the growth of probiotic strains present in the composition and in the indigenous microflora and exhibit a synergistic effect in vivo. [0034] As used herein, the term "subject" refers to any living organism such as an animal or human being in need of treatment for, or susceptible to, a condition involving an unwanted or unwanted microorganism, for example, a particular treatment to have an unwanted gastrointestinal pathogen as defined below. The term subject includes, but is not limited to, humans, non-human primates and monkey species, farm animals such as, pigs, goats and horses, domestic mammals such as dogs and. cats, laboratory animals including rodents such as mice, rats and guinea pigs. The term does not denote a particular age or sex. Thus, adult and newborn subjects, whether male or female, are meant to be covered). In preferred embodiments, the subject is a mammal, including humans and non-human mammals. In the most preferred embodiment, the subject is a human being. As used herein, the term "pathogenic" refers to a substance or condition that has the ability to cause disease. [0035] As used in this document, the terms "gastrointestinal pathogen" or "enteropathogen" include microbes with pathogenicity to the gastrointestinal tract (from the esophagus down to the rectum). Includes enterobacteria, enterococci, corynebacteria, subspecies of Mycobacterium avium paratuberculosis, Brachyspira hyodysenteriae, Lawsonia intracellulars, Campilobacter, Clostridia. Gastrointestinal pathogenic bacteria can include bacteria of the genus Salmonella, Shigella, Staphylococcus, Campylobacter jejuni, Clostridium, Escherichia coli, Yersinia, Vibrio cholerae, and others. [0036] As used herein, the terms "bacteriocins" or "bacteriocin-like substances" are proteinaceous toxins produced by bacteria to inhibit the growth of similar or closely related bacterial strains. [0037] As used in this document, the term "treatment" includes the attempt to prevent, remedy, improve, and prevent the relapse of a health problem in a subject, usually following a diagnosis. BRIEF DESCRIPTION OF THE FIGURES [0038] Figure 1 Algorithm for the gastrointestinal transit stimulator (GITS). Figure 2 Bacterial counts during stimulation of gastrointestinal transit (GITS) as determined by qPCR. Figure 3 Experimental design of the prevention of ICD in a murine model with a symbiotic, probiotic and prebiotic mixture. Figure 4. Cecal count of grouped caecal contents of all animals within a group. Figure 5 Histopathology of cecal tissues of animals Figure 6 Results of qPCR for cecal LAB and bifidobacteria in a symbiotic group and a control group. DETAILED DESCRIPTION OF THE INVENTION [0039] The present invention relates to symbiotic compositions comprising at least two probiotic strains of the genus Lactobacilli (LAB) and / or Bifidobacteria (Bif) and one or more prebiotic substances. At least one of the bacterial strains should be able to degrade starch, and at least one of the prebiotic substances present in the composition should be starch. Bacterial strains should have the ability to adhere to the gut and inhibit toxins A and B produced by C. difficile, but not the growth of each other. In addition, at least one or more prebiotic substances present in the composition should increase the growth of probiotic strains, but not that of gastrointestinal pathogens. The symbiotic compositions of the present invention are advantageously used for the colonization of a subject's intestinal mucosa to prevent, treat, ameliorate symptoms of, and prevent relapse of antibiotic-associated diarrhea (AAD), and / or infections caused by gastrointestinal pathogens. [0040] In the present study more than 75 different probiotic strains of the genus Lactobacillus and Bifidobacteria were screened and characterized in relation to beneficial properties such as adhesion to the mucus layer of the intestine, antimicrobial activities against C. difficile (CD) and / or other intestinal pathogens, degradation of prebiotic substances and the production of antioxidants etc. Surprisingly, these properties were found to be very strain specific and not general for all strains of a genus. [0041] Lactobacilli belong to a group of bacteria (microaerophilic) comprising more than 100 different Lactobacillus species that produce lactic acid during growth. They are the dominant part of the normal vaginal flora and intestines of newborns, but they also form part of the normal adult flora. Lactobacilli are able to grow at low pH and tolerate> 20% bile in the growth medium. The production of lactic acid makes your environment acidic, which inhibits the growth of some harmful bacteria. L. acidophilus, L. plantarium, L. casei, L. paracasei, L. reuterí, L. rhamnosus, L. bifidus, and L bulgaricus are some important species of the genus Lactobacillus that can be used in the composition of the present invention. [0042] Bifidobacteria belong to an anaerobic group of bacteria that colonize the intestines of newborns and gradually diminish with age. They exert beneficial effects during growth including the regulation of intestinal microbial homeostasis, the inhibition of harmful pathogens and bacteria that colonize and / or infect the intestinal mucosa, the modulation of systemic and local immune responses, the repression of pro-carcinogenic enzyme activities within microbiota, the production of vitamins, and the bioconversion of a number of dietary compounds into bioactive molecules. B. longum, B. breve, B. animalis, B. bifidum, B. infantil are examples of species of the genus Bifidobacterium that can be used in the composition of the present invention. [0043] Following the initial screening, six strains (ie, LAB LU28, LAB LU 33, Bif LU 10, Bif LU 29 and Bif LU 30) were eventually selected from the group of more than 75 probiotic strains based on their beneficial properties as discussed above. The selected strains were thereafter tested for their ability to survive and multiply, as well as exhibiting antimicrobial activity (AMA) during growth in the presence of each other, that is, during co-culture. All selected strains of bifidobacteria and lactobacilli survived co-culture well and did not produce bacteriocin-like substances against each other. [0044] The selected strains were also investigated in relation to their use of prebiotics such as galactooligosaccharides (GOS), Xylooligosaccharides (XOS), isomaltose oligosaccharides (IMOS), fructo-oligosaccharides (FOS), lactulose, arabic gum, beta glucan, xylan , pectin, inulin and / or soluble and resistant starch, when co-cultivated with one another. Co-culture of selected probiotic strains stimulated the growth of specific bacterial strains depending on their prebiotic degradation capacity in different combinations of prebiotics. Surprisingly, the co-culture of a strain that does not degrade starch and a strain that degrades starch, in the presence of starch as the only prebiotic substance available, stimulated the growth of the strain that does not degrade starch. The AMA of such compositions was retained against CD and other intestinal pathogens. This indicated a new concept of cross-feeding and demonstrates the synergy exhibited between the strains of the composition of the present invention. This concept is used when developing optimal compositions to be used in colonizing a subject's intestinal mucosa to prevent, treat, improve symptoms of and prevent relapse of antibiotic-associated diarrhea (AAD), and / or infections caused by gastrointestinal pathogens. [0045] Cell-free supernatant (CFS) from Co-cultures of two or more of the selected strains with different combinations of prebiotics exhibited AMA against ESBL E. coli, S. aureus, C. difficile 2167 and NAPl / 027 pathogens. Surprisingly, AMA was retained when the CFS extract was diluted to 1: 500 against some pathogens and 1:10 against others, an activity that was significantly higher than that of strains grown as mono-cultures. This clearly shows that selected strains exhibit synergism with each other leading to high AΜA against pathogens. In addition, co-culture of a mixture of selected strains and CD, reduced growth of CD, and production of Toxin A and B by CD were strongly inhibited by the presence of the selected probiotic strains. [0046] In said composition it is an advantage, but not necessarily a requirement that one or more of the bacterial strains are exposed to acid, bile and / or mucin during the production of the bacterial strains. Exposure to acid and / or bile induces stress responses in bacteria that increase their ability to survive transport through the gastrointestinal tract and colonize the intestinal mucus layer where they produce antimicrobial activity (AMA) allowing strains to have beneficial effects. [0047] Exposure to acid may involve decreasing the pH of the culture broth in which one or more of the bacterial strains are grown in MRS media up to pH 2-5, preferably up to pH 2.5-4.5, more preferably pH to 3- 4, for 15-150 min, preferably for 20-140 min, more preferably for 30-130 min, more preferably for 40-120 min. Exposure to bile may involve the addition of 0.1-2.5% (w / vol), preferably 0.5-2%, more preferably 1.0-1.5% sodium taurocholate, or 1-10% (vol / vol), preferably 2-7%, more preferably 3-10% porcine bile, a culture broth for 2-8 h, preferably for 2.5-7 h, more preferably for 3-6 h during production of bacterial strains. Exposure to mucin involves growing bacterial strains in the presence of 0.01- 1% (vol / vol), preferably 0.03-0.7%, more preferably 0.05-0.5% mucin for 2-8 h , preferably for 2.5-7 h, more preferably for 3-6 h during the production of the bacterial strains. [0048] Usually bacteria are grown in a medium that is "fair" for growth. Exposure to acid, bile or mucin during growth is a stress for bacteria. As a defense, stress genes are induced that in turn induce the production of Heat Shock Proteins (HSP) and other stress proteins that make bacteria more robust. Exposure to acid and bile stress mimics the condition of the gastrointestinal tract. The stability, robustness and synergy of compositions of selected strains with prebiotics were confirmed in a simulator model of the gastrointestinal tract (GITS) as well as in mouse models in vivo. [0049] Based on studies regarding co-culture, co-feeding, ΑΜΑ against CD and intestinal pathogens, toxin inhibiting activity, ability to tolerate exposure to acids, bile and / or mucin, as well as in vitro simulations (model GITS) and mouse models in vivo, optimal components of the composition of the invention were selected. The composition of the invention comprises at least two probiotic strains of the genus Lactobacilli (LAB) and / or Bifidobacteria (Bif) and one or more prebiotic substances. In addition, at least one of the bacterial strains has the ability to degrade starch, and at least one of the prebiotic substances present in the composition is starch. [0050] Advantageously, the bacterial strain capable of degrading starch is of the genus Bifidobacteria, such as, for example, a species of Bifidobacterium breve or more specifically the strain Bif LU 10. The bacterial strain that degrades starch of the invention is able to degrade starch such as starch soluble (i.e., starch that can be degraded in the intestine), and / or resistant starch (i.e., starch that cannot be degraded in the intestine). Advantageously, the symbiotic composition of the invention further comprises a strain that does not degrade starch which is of the Lactobacillus paracasei species such as LAB LU 33. [0051] Thus, advantageous compositions of the present invention comprise at least Bif LU 10 and one or more of the strains LAB LU 23, LAB LU 28, LAB LU 33, BIF LU 29, and / or BIF LU 30. An additional advantageous composition comprises at least Bif LU 10, and LAB LU 33, or at least BIF LU 10, LAB LU 33, and BIF LU 30. Still an additional advantageous composition comprises at least BIF LU 10, LAB LU 33, BIF LU 30, and LAB LU 28. Advantages of the described compositions are disclosed below. [0052] The symbiotic composition of the invention may, in addition to starch, comprise additional prebiotic substances that are in the group consisting of disaccharides, oligosaccharides, and / or polysaccharides. The disaccharide can be lactulose. The oligosaccharides can belong to the group consisting of fructo-oligosaccharides (FOS), galactooligosaccharides (GOS), Xylooligosaccharides (XOS), chitosan oligosaccharides (kioses), isomaltose oligosaccharides (IMOS), arabic gums, oligosaccharides and oligosaccharides, oligosaccharides and oligosaccharides. Polysaccharides can belong to the group consisting of pectin, xylan, inulin, chitosan, arabinoxylan, and / or β-glucan. [0053] Preferably at least one or more of the additional prebiotic substances in addition to starch are from the group consisting of galactooligosaccharides (GOS), Xylooligosaccharides (XOS),. isomaltose oligosaccharides (IMOS), fructo-oligosaccharides (FOS) and / or lactulose. [0054] Thus, a composition of the invention can, for example, comprise two or more of the bacterial strains as described above, starch and one or more additional prebiotic substances from the group consisting of galactooligosaccharides (GOS), Xylooligosaccharides (XOS), isomaltose oligosaccharides (IMOS), fructo-oligosaccharides (FOS) and / or lactulose. [0055] The composition of the present invention can advantageously be used to colonize a subject's intestinal mucosa. As used herein the term "subject" refers to any living animal or human being in need of treatment for, or susceptible to, a condition involving an unwanted or unwanted gastrointestinal microorganism, for example, a particular treatment to have an unwanted gastrointestinal pathogenic infection as defined above. In preferred embodiments, the subject is a mammal, including humans and non-human mammals. Its use is particularly advantageous when the subject is a human being. [0056] In one embodiment of the invention the composition of the invention is used to prevent, treat, ameliorate symptoms of, and / or prevent relapse of diarrhea associated with Clostridium difficile (CDAD) and / or infections caused by gastrointestinal (GI) pathogens. As used herein, the term "gastrointestinal pathogens" refers to viruses, parasites and bacteria that can cause infections in a subject, for example, when the subject is a mammal such as a human. Gastrointestinal pathogenic bacteria can include bacteria of the genus Salmonella, Shigella, Staphylococcus, Campylobacter jejuni, Clostridium, Escherichia coli, Yersinia, Vibrio cholerae, and others. [0057] Advantageously the composition can be used to prevent, treat, ameliorate symptoms of, and / or prevent relapse of antibiotic-associated diarrhea (AAD) induced by strains of Clostridium difficile of different virulence and ribotypes. Clostridium difficile is an anaerobic species of the genus Clostridium which, at low counts, forms part of the normal intestinal flora. C. difficile is the most serious cause of antibiotic-associated diarrhea (AAD) and can lead to pseudomembranous colitis, a severe infection of the colon, often resulting from the eradication of normal intestinal flora by antibiotics. During growth C. difficile produces and secretes virulence factors, for example, Toxin A and B. Toxin A is toxic to all cells, while Toxin B is toxic to enterocytes as it damages cells and induces secretion (diarrhea). The composition of the invention can be used to prevent, treat, ameliorate symptoms of, and prevent relapse of antibiotic-associated diarrhea (AAD) induced by Clostridium difficile strains of the group consisting of CD NAPl / 027, CD 1939, CD2167, CD ribotypes 1958, CD 2165, CD 2166, CD2168, CD 027 and CD 1551. [0058] A further aspect of the invention provides a use of the composition described above, for the manufacture of a medicament for use in colonizing a subject's intestinal mucosa and to prevent, treat, ameliorate symptoms of, and prevent relapse of antibiotic-associated diarrhea (AAD ), and / or infections caused by gastrointestinal pathogens in said subject. [0059] A further aspect of the invention provides a use of the composition described above, for the manufacture of a medicament for use in the treatment of a subject suffering from antibiotic-associated diarrhea (AAD), and / or infections caused by gastrointestinal pathogens. [0060] A further aspect of the invention provides a use of the composition described above, for the manufacture of a medicament for use in preventing a relapse of antibiotic-associated diarrhea (AAD), and / or infections caused by gastrointestinal pathogens in a subject. [0061] The prebiotic substances and probiotic strains of the composition in the present invention can be isolated at any level of purity by standard methods and purification can be achieved by conventional means known to those skilled in the art, such as distillation, recrystallization and chromatography. [0062] The cultured bacterial cells to be used in the composition are separated from the broth with any method including, without limitation, centrifugation, filtration or decantation. The cells separated from the fermentation broth are optionally washed with water, saline (0.9% NaCl) or with any suitable buffer. The obtained wet cell mass can be dried by any suitable method and preferably by lyophilization. [0063] The prebiotic substances and probiotic strains of the composition in the present invention can be administered separately or in combination with pharmaceutically acceptable carriers or diluents, and such administration can be carried out in single or multiple doses. [0064] In a composition of the present invention, the prebiotic component is present in an amount comprised from 5 to 99% by weight, based on the total weight of the composition; preferably from 30% to 95%, more preferably from 50 to 90% by weight. In turn, the probiotic component is present in an amount from 1 to 15% by weight, based on the total weight of the composition; preferably from 5 to 10%. The part missing up to 100% by weight of the symbiotic composition, if any, consists of additional substances such as adjuvants and / or excipients or appropriate additives / carriers. [0065] In a pharmaceutical composition (for example, tablets) the composition of the invention is comprised from 40 to 70% by weight, based on the total weight of the pharmaceutical composition, and the remainder is made of pharmaceutically acceptable adjuvants and / or excipients. In a food composition (for example, yogurt or chocolate) the symbiotic composition is comprised from 1 to 15% by weight, based on the total weight of the food composition. [0066] In a preferred embodiment, the symbiotic composition contains bacterial strains in an amount ranging from 1x108 to 1x1013 CFU / g, with respect to the weight of the symbiotic composition, preferably from 1x109 to 1x1011 CFU / g. [0067] The compositions can, for example, be in the form of tablets, pills, sachets, vials, hard or soft capsules, aqueous or oily suspensions, aqueous or oily solutions, emulsions, powders, granules, syrups, elixirs, lozenges, reconstitutable powders, preparations liquids, creams, troches, hard candies, sprays, creams, ointments, jellies, gels, pastes, injectable solutions, liquid aerosols, dry powder formulations, HFA aerosols or organic or inorganic acid addition salts. [0068] The compositions of the invention may be in a form suitable for administration via the oral route, or by inhalation or insufflation (for example, nasal, tracheal, bronchial). [0069] For oral, buccal or sublingual administration, the prebiotic substances and probiotic strains of the present invention can be combined with various excipients. Liquid compositions for oral administration may be in the form of, for example, emulsions, syrups, or elixirs, or may be presented as a dry product for reconstitution with water or another suitable vehicle before use. Other suitable fillers, binders, disintegrants, lubricants and excipients are well known to a person skilled in the art. [0070] The invention also belongs to a composition as defined above, wherein the composition is at least one of or part of a food composition, a food supplement, a nutraceutical composition, a pharmaceutical composition and animal feed. [0071] A further aspect of the invention provides a method for colonizing the intestinal mucosa, and preventing, treating, ameliorating symptoms of, and preventing a relapse of antibiotic-associated diarrhea (AAD) and / or infections caused by gastrointestinal pathogens in a subject said method comprising the steps of administering the composition as described above in an effective dose to the subject in need thereof. Depending on the disorder and patient to be treated and the route of administration, the compositions can be administered in varying doses. In a preferred embodiment, the composition contains bacterial strains in an amount ranging from 1x107 to 1x1013 CFU / dose and bacterial strain, preferably from 1x109 to 1x1011 CFU / dose and bacterial strain. [0072] The advantages of the present invention will now be illustrated by means of experiments. However, the experiments described below are only given as examples and should not be limited to the present invention. Other solutions, uses, objectives, and functions within the scope of the invention as in the claims should be apparent to the person skilled in the art. Reason for the selection of strains for the composition of the invention [0073] The main selection criteria for most promising strains from a used strain bank were antimicrobial activity (AMA) against intestinal pathogens including Clostridium difficile, and ability to adhere to the intestinal wall, as measured by Congo red binding (CRB) and testing of aggregation of salt (SAT). The following criterion was the fermentation of at least one or more than one prebiotic substance. The results of screening the tested strains are shown in Table 1. [0074] Cell surface hydrophobicity (CSH) is an important property of a microbe to bind and interact in the intestine and compete with pathogens in the mucus layer. CSH was determined based on CRB and SAT assays as follows. CRB was performed by incubating cells washed with Congo red (100 micrograms / ml in PBS) for 10 min followed by centrifugation (9,000 g * 30 min). Congo red residual in the supernatant was determined by measuring the absorbance at 480 nm. Congo red in phosphate buffered saline (PBS, pH 7.2, 0.015 M) was used as a control. CRB is expressed as a percentage of binding of Congo red. Therefore, the closer the result is to 100, the higher the hydrophobicity of the cell surface. CSH was determined by the Salt Aggregation Test (SAT) Ten microliters of cell suspension washed in PBS were mixed with 10 microliters of ammonium sulfate at pH 6.8 of various molarities ranging from 0.02 M to 4 M on a slide of glass. After one minute, aggregation was observed. The results of SAT are expressed as the lowest concentration of salt (M) in which the strain aggregates. Lower salt concentration required for aggregation means higher cell surface hydrophobicity. [0075] The AMA of potential probiotic strains was determined against the intestinal pathogens ESBL E. coli, S. aureus, Salmonella typhimuríum and four different strains of C. difficile using a microtiter plate assay (MTP) as follows: Supernatant culture filtrates Free cells (CFS) were harvested from 24 h cultures of lactobacilli and bifidobacteria grown in MRS (De Man Rogosa Sharpe) and MRSC broth (MRS with 0.05% (w / v) L-cysteine hydrochloride) by centrifugation (3,200 g, 20 min, 4 ° C) and the supernatant was sterilized in a filter using a 0.2 micrometer filter. To determine AMA, the CFS was added to an MTP. Different dilutions (1: 1, 1:10, 1: 100 and 1: 500) were prepared in sterile heart and brain infusion broth (BHI). 100 microliters of the supernatant were added to microtiter wells and incubated at 37 ° C overnight anaerobically using an Anoxomat® culture system (MART, Netherlands) to equilibrate. Gut pathogen cells were grown on Fructose Fastidious agar plates for 24 h anaerobically. The cells were washed twice in PBS, and resuspended in sterile PBS. Ten microliters of intestinal pathogen cells with A620 = 0.02 were prepared in BHI broth and added to the pre-reduced MTP overnight. Growth was measured after 48 h (CD pathogens) / 24 h (other pathogens) at OD62o using a plate reader and the result was expressed as a percentage of intestinal pathogen growth inhibition calculated in relation to growth in a control well without CFS. [0076] ODt and ODc represent the growth of CD in the presence and absence of LAB CFS or bifidobacteria. Similarly, AMA from co-cultured extract of lactobacilli and bifidobacteria was determined against CD. The same formula was used for all intestinal pathogens. [0077] A preliminary screening of the ability of potential probiotic strains to degrade prebiotics was performed as follows: Lactobacilli and Bifidobacteria strains were initially grown on MRS / MRSC agar under micro-aerophilic and anaerobic conditions at 37ºC. A single colony of each strain was then spread as a small patch on basal MRS agar without glucose and with 1% (w / vol) of prebiotic (Fructooligosaccharides (FOS), Xylooligosaccharides (XOS), galactooligosaccharides (GOS), Inulin, soluble starch (SS), resistant starch (RS), pectin, isomaltooligosaccharides (IMOS), Lactulose) for Lactobacilli or yeast extract peptone agar (PY) supplemented with 0.05% (w / v) L hydrochloride agar -cysteine for bifidobacteria with 1% (w / vol) of prebiotic (FOS, FOS (Orafti), XOS, GOS, Inulin, SS, RS, pectin, IMOS, Lactulose) as the main source of carbon, and 30 mg of purple of bromocresol per liter and was incubated under microaerophilic (for lactobacilli) or anaerobic (for bifidobacteria) conditions at 37 ° C for 48 h. The degradation capacity of FOS, FOS (Orafti), XOS, GOS, inulin, SS, RS and pectin by various LAB and bifidobacteria can be seen in Table 1 (see footnote). [0078] Table 1. Results of screening for binding to Congo red, salt aggregation test, AMA and degradation of prebiotics. [0079] Abbreviations are as follows: - H- High activity - ≥70% inhibition, Moderate-- 41-69% inhibition, Low ≤40% inhibition, nd- not determined; Vw + - very weak; 2+ strongly positive; 3+ very strongly positive. Based on the results of the experiments shown in Table 1, probiotic strains presented in Table 2 were selected for further experiments. [0080] Based on the results of the experiments shown in Table 1, probiotic strains presented in Table 2 were selected for further experiments. [0081] Based on the results of the experiments shown in Table 1, probiotic strains presented in Table 2 were selected for further experiments. Table 2. Selected list of probiotic candidates. [0082] The selected probiotic strains were deposited on November 24, 2010 with the Belgian Coordinated Collections of Microorganisms (BCCM), Laboratorium voor Microbiologie Bacterienverzameling (LMG), Universiteit Gent, K.L. Ledenganckstraat 35, 9000 Gent, Belgium (website: http: //bccm.belspo.ser) with the following Cepe deposit numbers: LAB LU 33: LMG P-26118, LAB LU 28: LMG P-26120, BIF LU 10: LMG P-26117, BIF LU 30: LMG P- 26116, BIF LU 29: LMG P-26115, LAB LU 23: LMG-P-26119 Co-culture of probiotic strains [0083] Different combinations of the selected bifidobacteria and LAB strains (Table 2) were tested to determine a possible synergy and compatibility of these strains with each other. To determine whether bacteriocin-like substances are produced by a specific strain, AMA of neutralized extracts from each strain was determined against other strains using the MTP assay. AMA extracts were obtained as in the experimental procedure described above. [0084] CFS obtained as in the experimental procedure described above were neutralized to pH 7 using 5N NaOH. AMA of CFS neutralized from selected bifidobacteria and lactobacilli was determined against each other using an MTP assay. Neutralized extracts of selected strains of lactobacilli or bifidobacteria used in the study did not exhibit AMA against each other (lactobacilli or bifidobacteria). In addition, they did not inhibit other lactobacilli and bifidobacteria that were used as reference strains, indicating that selected strains of bifidobacteria and lactobacilli do not produce bacteriocin-like substances one on one. other. This property of the strains was useful in the development of mixtures of suitable strains in a "symbiotic formulation" to prevent and treat infection caused by intestinal pathogens and C. difficile. [0085] Many gastrointestinal infections are caused by Salmonella, Campylobacter jejuni, and ESBL E. colí, while AAD is mainly caused by CD and MRSA. Therefore, after confirming that the selected strains of LAB and bifidobacteria from Table 2 do not inhibit each other, they were co-cultured in MRSC broth and its potential AMA against CD including hypervirulent CD 027 / NAP1, ESBL E. coli, S. aureus , and Salmonella typhimurium was determined using an MTP assay. [0086] Activated culture of the selected strains of LAB and bifidobacteria from Table 2 were co-cultured by inoculating 10% of inoculum of strain (total of all strains) of LAB and / or different bifidobacteria in 5 ml of pre-reduced MRSC broth and left to grow under anaerobic conditions using an Anoxomat jar at 37 ° C for 24 h. After 24 h, cultures were harvested by centrifugation and the supernatant was sterilized in a filter using a 0.22 micrometer filter. CFS was used to determine AMA against CD and other pathogens using the MPT assay as described above or previously. Growth was measured after 48 h (pathogens CD) / 24 h (other pathogens) at OD62o using a plate reader and the result was expressed as a percentage of growth inhibition of pathogens calculated in relation to growth in a control well without CFS. [0087] Co-cultures of different combinations of LAB LU 28, LAB LU 33, Bif LU 10 and Bif LU 30 showed high AMA against Salmonella typhimurium, E. coli, C. difficile CD NAPl / 027 and S. aureus. Surprisingly, AMA was retained when the CFS extract was diluted to 1: 500 against pathogens (CD 027 and S. aureus) and 1:10 against S. typhimurium and ESBL E. coli, which was not found when strains were tested. as mono-cultures (Table 3 & Table 4). The composition containing LAB LU 28, LAB LU 33, Bif LU 10 and Bif LU 30 showed a higher AMA at 1:10 dilution against S. typhimurium and ESBL E. coli that was found with other combinations (Table 4). This clearly shows that selected strains exhibit synergism between strains leading to high AMA against pathogens. Table 3. AMA of different combinations of co-cultures containing probiotic strain against C. difficile NAPl / 027, C. difficile 2167 and MRSA S. aureus [0088] In addition, AMA produced by the strains selected against C. difficile correlated well with the reduced amount of toxin produced by the hypervirulent strain CD NAP1 / 027. No toxin was detected from the CD NAP1 / 027 strain when grown in the presence of CFS extract from selected co-cultured strains diluted to 1:10. When the NAP1 / 027 extract containing high amounts of toxin A and toxin B was incubated with LAB and live bifidobacteria, toxicity was inhibited, indicating that the selected strains of LAB and bifidobacteria exhibit antitoxin activity. CFS AMA produced by different combinations of LAB LU 28, LAB LU 33, Bif LU 10 and Bif LU 30 is attributed not only to acids, but also to heat-stable extracellular antimicrobial proteins / peptides. A composition comprising the strains LAB LU 28, LAB LU 33, Bif LU 10 and Bif LU 30 showed AMA against hypervirulent strain of CD NAP1 / 027, S. aureus, S. typhimurium and ESBL E. coli (Table 3 & Table 4) . [0089] In addition, the combination of probiotic strains selected above was co-cultured with CD NAPl / 027 in yeast peptone protease glucose extract with 0.05% (w / v) media of L-cysteine hydrochloride (pH 7, two). CD NAPl / 027 showed a reduction of 2 log of growth cfu and the production of CD toxin A and toxin B was strongly inhibited after 24 h of growth compared to CD grown separately in PYG. It can therefore be concluded that a composition including two or more of the strains LAB LU 28, LAB LU 33, Bif 10 and Bif 30 exhibits synergy leading to increased AMA against intestinal pathogens. Co-feeding: Probiotics + Prebiotics [0090] In order to develop a multi-strain probiotic or a symbiotic, it is important to select effective strains with high prebiotic scores and / or prebiotic index to restore the intestinal microbiota with beneficial microbes in the subject's intestine. [0091] The initial screening included FOS, GOS, XOS; IMOS and Lactulose (Table 5). Also, other natural polysaccharides such as wheat resistant starch (RS), gum arabic, beta glucan, xylan, pectin and inulin were evaluated for their prebiotic potential. [0092] FOS is well known for its bifidogenic and lactogenic effect, but it can cause mucosal irritation in humans and increase the translocation of Salmonella enterica in antibiotic-treated mice, a disadvantage that encourages inventors to screen GOS, IMOS, XOS and lactulose as a prebiotic instead of FOS. [0093] Most of the selected probiotic strains (Table 2) degraded more than a prebiotic component (Table 5). A prebiotic score (PS) was developed for each strain selected by determining the relative growth of each strain in an individual prebiotic compared to glucose. Table 5. Prebiotic score for LAB and bifidobacteria [0094] Co-culture of probiotics mixed with different combinations of prebiotics [0095] In the co-culture experiment above, it was shown that the selected strains were compatible with each other since they did not exhibit AMA against each other. The same strains selected were co-cultivated in the presence of a single prebiotic, a combination of prebiotics and a combination of prebiotics with SS under conditions of uncontrolled pH, to further investigate the possibility of synergism between the probiotic strains. [0096] The strains LAB LU 28, LAB LU 33, BIF LU 10 and BIF LU 30 were mixed and subcultured on MRSC agar at 37 ° C for 48 h. Single colonies were inoculated in 5 ml of a pre-reduced MRSC broth and subcultured three times. Each culture was harvested, washed as above and resuspended in PBS. The four selected probiotic strains were inoculated as a mixture to achieve a final absorbance of 0.5 units (that is, 0.125 per strain) in 5 ml of pre-reduced MRSC broth with 1% (w / v) (um) GOS, IMOS and soluble starch (SS) in a mixture (1: 1: 1), (b) IMOS and GOS (1: 1), (c) GOS and SS (1: 1), (d) GOS and (e) SS tubes were incubated under anaerobic condition for 24 h. Samples taken after 0, and 24 h and 100 microliters of culture broth were serially diluted and 50 microliters were spread on MRS agar (for LAB) and Bereens agar (for bifidobacteria), to determine viable CFU / ml counts. [0097] The total number of Lactobacillus and bifidobacteria in different combinations of individual and mixed prebiotics is shown in Table 6. With glucose (GLU), GOS and IMOS / GOS, the total bifidobacteria counts were higher than total LAB. With SS, the increases in the number of LAB and bifidobacteria were the same. With SS / GOS and SS / IMOS / GOS, total LAB counts were higher than bifidobacteria counts. The order of increase in ufc / ml log for LAB is SS / IMOS / GOS> SS / GOS>GOS>SS> IMOS / GOS> GLU and for IMOS / GOS bifidobacteria>GOS>GLU> SS / IMOS / GOS> SS > SS / GOS (Table 6). Table 6. Total lactobacilli and total bifidobacteria during the co-culture experiment after 0 and 24 h of growth. [0098] To elucidate a possible co-feeding and increased growth of the strain that does not degrade starch LAB LU 33 with the strain that degrades starch Bif LU 10, these strains were co-cultivated in MRSC broth with 1% (w / v) of SS as single carbon source. The co-culture of Bif LU 10 and LAB LU 33 improved the growth of LAB LU 33 .. The intermediate metabolites produced during starch degradation supported the growth of LAB LU 33 (Table 7). Starch degradation is important to maintain a normal colon environment, and to improve the growth of other beneficial microbes to restore the intestinal microflora. The decrease in pH during starch metabolism did not inhibit LAB LU 33, and both strains are compatible with each other and show synergistic activity. The synergy exhibited by LAB 33 and Bif LU 10 surprisingly became strain specific. When LAB LU 28, also a strain that does not degrade starch, and Bif LU 10, were grown in the presence of RS, the growth of LAB LU 28 was not stimulated. The same observation was made when the well-known probiotic strain L. rhamnosus GG, a strain that does not degrade starch, was co-cultivated with the strain that degrades starch Bif LU 10 in the presence of SS; the growth of L. rhamnosus GG was not stimulated. These two examples indicate that cross-feeding is specific for selected strains used in combination with one another. Cross-feeding is apparently not an obvious property even among strains of the same genus. Table 7. Co-feeding of LAB that does not degrade starch with Bif LU 10 that degrades starch in SS [0099] Net increase in LAB ufc log in a co-culture is calculated using the formula = (Ufc log at T 48h - F8 ufc log at F8 with B 46+ soluble starch) - (Ufc log at T 48h - Ufc log at T0h of F8 in the presence of soluble starch). [0100] AΜΑ of extract co-cultured against human AMA pathogens from extracts from two or more of the selected strains (Table 2) co-cultured with different combinations of prebiotics was determined against intestinal pathogens. It was found that all CFS grown with different combinations of prebiotics exhibited AMA against pathogens ESBL E. coli, S. aureus, C. difficile 2167 and NAP1 / 027 (Table 8). When the co-cultured extract CFS was incubated with CD extract containing toxin,> 70% of the toxic effect was inhibited, indicating that the acids produced in the CFS exhibit antitoxin activity. Table 8. AMA displayed by the selected strains LAB LU 28, LAB LU 33, Bif LU 10 and Bif LU 30 during co-culture in different combinations of prebiotics. [0101] # toxin level was not detected in these samples ie the toxins were inhibited; toxin A and toxin B, virulence factor responsible for CD infection determined by ELISA assay. [0102] It can be concluded that the strains selected in the present composition have a high capacity to degrade prebiotics. Co-cultivation of selected strains with different combinations of prebiotics gave different LAB / bif ratios depending on the ability of the strains to degrade prebiotics. It was also found that metabolism by the strain that degrades Bif LU 10 starch stimulated the growth of the strain that does not degrade starch LAB LU 33. It should also be noted that the selected strains exhibited high AMA against intestinal pathogens, depending on the combination of different prebiotics used during the culture (see Table 8). Co-feeding: Pathogen + prebiotics [0103] As described above, C. difficile, ESBL E. coli, S. aureus, S. typhimurium, are human pathogens. It is therefore essential to examine whether such pathogens are capable of degrading and using the prebiotics present in the symbiotic mixture. Tests showed that none of the human pathogens; five clinical isolates of C. difficile including the hypervirulent strain NAP1 / 027, S. aureus, ESBL E. coli, and S. typhimurium from Hospital LU were able to use FOS, GOS, IMOS, XOS, inulin, RS, SS, pectin or xylan. Therefore, human pathogens did not exhibit prebiotic degradation capacity, which is very encouraging for the development of a cocktail of probiotics and prebiotics to combat intestinal infection. [0104] Stress pulse and in vitro gastrointestinal tract (GIT) simulation for the evaluation of selected strains [0105] A simple and reliable in vitro method was developed to simulate gastric transit conditions in vivo. This was done by exposing the selected probiotic strains to a combined acid (for 30 min), and bile stress pulse for 4 h to mimic gastrointestinal transit (GITS) in vivo at 37 ° C, aerobically (LAB) and anaerobically ( bifidobacteria). First, the cells were subjected to acid stress in the MRSC / MRS medium at pH 2.5. After 30 min, the cells were washed with PBS and stressed with MRSC / MRS comprising 5% porcine bile (v / v) for 4 h. The viability of the strains was determined after 30 min and 4 h. MRSC broth without acid or bile stress was used as a control. To study the prebiotic degradation capacity of stressed pulsed cells, they were also washed and inoculated in MRSC broth with different prebiotics or glucose. Non-stressed cells were used as a control. [0106] Three strains, LAB LU 28, LAB LU 33 and LGG, showed 100% viability after a stress pulse. BIF LU 30 and Bif LU 10 showed 100 and 40% viability respectively at the end of the bile phase in the GI transit model. The reference strain, B. lactis JCM 10602 (Bbl2), showed 85% viability after GI transit. The order of robustness, that is, tolerance in a traffic simulation similar to GI, is as follows: Bif LU 30> B. lactis JCM 10602> Bif LU 10. [0107] Ideally in vivo, the selected strains reach various parts of the intestine in a viable form and multiply well using prebiotics as food in order to exercise their probiotic functions. The ability of strains in the probiotic mixture to metabolize prebiotic supplements was analyzed in a Transit similar to GI, that is, after a stress pulse. LAB LU 28 stress and non-stressed pulse cells showed similar growth with GOS and glucose. Bif LU 10 stress pulse cells showed a longer lag phase, but after 24 h their growth pattern was similar to that of cells not stressed in the presence of IMOS, GOS and FOS. In addition, the growth of Bif LU 10 with stress pulse was higher in GOS, IMOS, FOS compared to glucose. The 'Bif LU 30 strain showed the same growth kinetics as non-stressed cells when grown with GOS, XOS and glucose. [0108] For a composition, probiotic strains will be selected based on robustness (ie, stress pulse), AMA against C. difficile and other enteric pathogens, the ability to use prebiotics, the ability to reach the intestine without losing its metabolic activity, the ability to multiply in the presence of prebiotics from a symbiotic mixture and exert their probiotic effects. [0109] CFS of LAB LU 28 and LAB LU 33 grown in the presence of 5% porcine bile retained more than 60% AMA against S. aureus, S. typhímuríum, C. difficile 2167 and C. difficile NAP1 / 027. Bif LU 10 and Bif LU 30 grown in the presence of 5% porcine bile retained more than 60% AMA against C. difficile 2167 and C. difficile 027. The selected strains grew in the presence of 5% porcine bile retained AMA against C. difficile and other gastrointestinal pathogens (including S. typhimurium, ESBL E. coli, S. aureus). [0110] Robust cells produced after a stress pulse will be useful to produce higher cell yield during lyophilization and the final packaging of. symbiotic formulation with prebiotics and RS. [0111] Use of a Gastrointestinal Tract Simulator (GITS) to assess the survival of selected probiotic strains in mixed cultures. [0112] The GITS consists of a 1 L "Biobundle" fermenter, an ADI 1030 biocontroller and scales, connected to the PC and controlled by a "BioXpert" cultivation program. Temperature, pH, culture volume, agitation, oxygen content and liquid velocity rates (ie, HCl, NaHC03, bile salts, feed medium) are controlled by the program. The GITS is a fermenter with several vessels (P1-P5) that simulate the gastrointestinal tract (Figure 1). [0113] A bacterial suspension is injected and remains in the first vessel that simulates the stomach (pH 3.0), for 3 h. The bacterial suspension is then pumped into a second vessel that simulates the small intestine with bile, pH 6.5, and the large intestine (dilution, pH 6.0). [0114] At the beginning of the simulation, 100 ml of 0.01 M HCl were added to fermentates to simulate an empty stomach. The selected strains of multi-strand probiotics (i) Bif LU 10, Bif LU 29, LAB LU 28 (ii) Bif LU 10, Bif LU 29, Bif LU 30, LAB LU 28 (iii) Bif LU 10, Bif LU 30, LAB LU 28, LAB LU 33 in 200 ml "model food" with medium containing yeast extract tryptone containing cysteine HC1 with mixture of prebiotics: FOS, GOS, XOS were pumped into the fermenter. [0115] As shown in Figure 1, Pl, P2, P3, P4, and P5 show the key sampling points that correspond to the beginning of the experiment (Pl), gastric phase (P2), bile phase (P3); dilution phase to remove bile (P4) and at the end of the experiment (P5). The pH in the vessel was titrated to 3.0 by the addition of 1 M HCl at a rate of 20 mmol h ”1 to simulate stomach conditions. After pH 3 was reached, the content of the bioreactor was adjusted to pH 6.0 by the addition of 1 M NaHC03. Porcine bile (30 ml of 30% solution) up to 3% was added to the fermenter and incubated for 30 min. The content was diluted until full experiment for 24 h with a dilution medium containing yeast extract with tryptone containing cysteine HC1 with a mixture of prebiotics from FOS, GOS, XOS (3g / L per pprebiotic). Colony-forming bacteria were listed as described above in the co-culture experiment during different phases of the simulation. The REP-PCR fingerprinting analysis with primer (GTG) 5 was performed by 20-40 colonies selected from the beginning and end of the experiments. Bacterial cells were quantified in terms of the number of total DNA copies using qPCR. The concentrations of organic acids (lactate, acetate, formate) and ethanol in the culture media were analyzed by liquid chromatography (Alliance 2795 system), using a BioRad HPX-87H column (Hercules, CA) with an isocratic elution of 0.005 M H2S04 at a flow rate 0.6 mL min-1 and at 35 ° C. Refractive index (IR) detector (model 2414; Waters Corp) was used for the detection and quantification of substances. [0116] In a composition containing Bif LU 10, Bif LU 29, and LAB LU 28 and the mixture of prebiotics FOS, XOS or GOS, the strains Bif LU 10 and LAB LU 28 survived well during the simulated GIT conditions (Table 9). A decrease in Bif LU 10 was more pronounced during the acid and bile incubation and increased during the dilution phase. (The numbers of BIF LU 29 were significantly lower at the end of the experiment and this strain was not detected in the culture). Table 9. Bacterial numbers (log10 cfu ml-1) as counted on MRS agar. The total number was listed on MRS-C anaerobically agar, LAB LU 28 on MRS agar aerobically. [0117] Production of lactate, acetate and ethanol in a 2: 5: 1 ratio suggests better growth of bifidobacteria during the "large intestine" phase. However, lactobacilli can theoretically produce acetate also under conditions of limited glucose. [0118] With a composition containing Bif LU 10, Bif LU 29, Bif LU 30, LAB LU 28 in equal quantities at the beginning of the experiment, the strain distribution was about 73% of LAB LU 28, 21% of Bif LU 30 and 6 Bif LU 10% at the end of the GITS experiment. These results indicate good survival and growth of Bif LU 10, Bif LU 30 and LAB LU 28 in this combination. With a composition containing the strains LAB LU 28, LAB LU 33, Bif LU 10 and Bif LU 30 with a mixture of prebiotics containing FOS, XO S, GOS, no significant decrease in the numbers of LAB or bifidobacteria was detected at the end of the experiment. GITS. [0119] Each biomass was analyzed by qPCR for total DNA copy numbers of the strains of LAB and bifidobacteria as well as the proportion of LAB LU 28, LAB LU 33, Bif LU 10 and Bif LU 30 (Figure 2). The results showed that the numbers of log copies of LAB LU 28, LAB LU 33, and Bif LU 30 remained the same after 20 h and at the end of the experiment. [0120] The strains LAB LU 28 and LAB LU 33 survived acid and bile stress well and were able to grow with oligosaccharides as a carbon source. The proportion of LAB LU 28 and LAB LU 33 compared to the other strains present in the mixture increased significantly during the simulation, according to the results of the rep-PCR. [0121] Bif LU 10 and Bif. LU 30 were detected at the end of the experiment, although their proportion in the probiotic mixture had decreased during the simulation. Bif LU 29 is less tolerant to bile and the counts were always lower compared to the other strains at the beginning of the experiment and were not detected at the end of the experiment. [0122] At the start of the simulation, LAB colony counts were always higher compared to Bif LU 10 and Bif LU 30, and LAB were able to multiply successfully during the dilution phase. Bifidobacteria recovered better from acid / bile stress than LAB strains, despite a more severe initial decline during acid / bile treatments. This is due to a preferred consumption of oligosaccharides compared to the strains of LAB during the dilution phase. There is a good correlation between single strain studies as described in the stress pulsation section below and co-cultures of these probiotic strains, confirming their robustness in the GI-like transit model. [0123] It is noteworthy that in a GITS experiment carried out with LAB LU 28, LAB LU 33, Bif LU 10, Bif LU 30 and B. pseudocatenulatum 1200 strains, in which SS (5 g / L) and GOS (5 g / L ) were used as main carbon sources, the LAB LU 33 strain was the strongest in this combination with SS / GOS despite the fact that this strain does not use SS or GOS. [0124] The GITS experiment confirmed the new concept of cross-feeding exhibited by Bif LU 10 and LAB LU 33 when grown in the presence of SS and GOS. LAB LU 33 is not able to use SS or GOS. However, when grown in the presence of other selected strains, especially the only strain that degrades starch in the composition, that is, Bif LU 10 and SS / GOS, the LAB LU 33 counts increased. In addition, the robustness of strains during GIT transit was also seen. It can be concluded that a composition containing a mixture of probiotics of LAB LU 28, LAB LU 33, Bif LU 10 and Bif LU 30 is stable in the transit model similar to GI in a single vessel GITS model. [0125] In these experiments, strains were selected based on a high prebiotic score. All four strains selected were grown in the presence of prebiotics and starch to draw a synergistic symbiotic mixture. These strains in the symbiotic mixture were found to be compatible with each other and the LAB / bif ratio increased or decreased depending on the prebiotic degradation capacity of the strains (prebiotic score Table 5) as well as their AMA displayed against human pathogens. In addition, the synergy between probiotics and prebiotics increased the growth of probiotic strains that do not degrade starch in the presence of probiotic strains that degrade starch. The selected strains are robust, can withstand GI-like transit, can maintain metabolic activity, and are capable of metabolizing prebiotics. Infection prevention using mouse model [0126] The compositions of the present invention can advantageously be used to colonize a subject's intestinal mucosa, (and in particular) to prevent and treat infections, ameliorate symptoms, and prevent relapse of antibiotic-associated diarrhea (AAD) and / or infections caused by gastrointestinal pathogens in a subject. [0127] As described above, the selected strains (ie, LAB LU 28, LAB LU 33, Bif LU 10 and Bif LU 30) all have high AMA against CD NAP1 / 027, are robust in terms of survival in GITS simulation, have ability to degrade at least one or more prebiotics used in the mixture. To investigate the effect of selected probiotic strains grown in the presence of the selected prebiotics, different combinations were tested in vivo using a mouse model. The detailed experimental schedule is shown in Figure 3. C57BL / 6 mice from six to seven weeks of age were divided into four experimental groups. Group 1 (n = 5) the symbiotic group was treated with a "symbiotic mixture" consisting of RS, IMOS, GOS and LAB LU 28, LAB LU 33, BIF LU 10 & BIF LU 30; Group 2 (n = 6) the probiotic group, was treated with a "mixture of probiotics" consisting of LAB LU 28, LAB LU 33, BIF LU 10 & BIF LU 30; Group 3 (n = 6) was treated with a "mixture of prebiotics" consisting of RS, IMOS, GOS; and Group 4 (n = 7) comprised of "positive control" in which the animals were infected only with CD 027. Groups 1 and 2 were given a daily dose of 1 x 1010 cfu / mouse of each probiotic strain. [0128] The total prebiotic concentration was 5% (w / w) of the normal diet, calculated based on a daily feed consumption of 5 g per mouse. RS was mixed with a low protein rodent diet (R70, Lantmannen, Malmo, Sweden) and precipitates were prepared and fed daily. Group 4 (n = 7) was a control group, infected with the NAP1 / 027 strain and which did not receive any mixtures of symbiotics, prebiotics or probiotics. The indigenous mouse intestinal microflora was disrupted by giving a mixture of antibiotics for five days (days -15 to -11) diluted in the drinking water. A cocktail of kanamycin, gentamicin, colistin, metronidazole, and vancomycin antibiotics was prepared in drinking water and sterilized in a filter. On day nine (-9) all animals, including the control group, received a single dose of clindamycin (10 mg / kg) intraperitoneally. Groups 1-3 were fed a symbiotic, probiotic and prebiotic mixture for seven days (Figure 3A). On day zero, all animals were challenged with 106 cfu of NAP1 / 027 (10 cfu with mouse) per gastric tube. The feeding of symbiotics, probiotics or prebiotics of the respective groups was continued for another five days and on day six all animals were sacrificed by CO2 asphyxiation (Figure 3A). Fresh cecal contents were collected aseptically for culture tests, real-time quantitative PCR (qPCR), histopathology and toxin. Antibiotic treatment in the control group (Group 4) was initiated in such a way that C. difficile infection (ICD) would fall on the same day as for Groups 1-3. This was done to maintain the uniformity of the CD dose used to infect the animals and to reduce errors in experiments (Figure 3B). [0129] Total counts of colonies of lactobacilli, bifidobacteria and viable NAP1 / 027 viable cecal contents of all animals within a group were analyzed (Figure 4A). Colony counts of NAPl / 027 were determined on Fructose Fastidious plates with cefoxitin under anaerobic conditions for 72 h at 37 ° C. Viable counts were expressed as ufc log / 100 mg of cecal content. In addition, total DNA copy numbers as determined by qPCR of Bif LU 10, Bif LU 30, LAB LU 33 and LAB LU 28 in the caecal contents of different groups of animals. * P-value <0.05, was also determined (Figure 4B). [0130] It was found that feeding with a symbiotic composition comprising the four selected probiotic strains, with IMOS, GOS and RS prebiotics, prevented ICD compared to the control group where the animals were severely ill because of colitis. [0131] All animals in Groups 1-3 were healthy and no symptoms of diarrhea were observed. Three mice in Group 4 became severely ill after two days of ICD due to colitis and were therefore euthanized. [0132] Colony counts of caecal contents in Groups 1-3 showed a significant reduction in NAPl / 027 (P <0.05) compared to animals in Group 4. Lactobacillus colony counts were higher in Group 4 (P <0, 05) compared to the other groups. Colony counts of bifidobacteria were significantly higher in Groups 1 and 2 compared to Groups 3 and 4 (Figure 4A). Numbers of DNA log copies of total bifidobacteria, of copy numbers Bif LU 10, LAB LU 28 and LAB LU 33 were higher in Groups 1 and 2 compared to Groups 3 and 4 (P <0.05). The numbers of total lactobacillus log DNA copies were similar in all four groups (Figure 4B). In Group 1, the cecal content of 3/5 mice showed a moderate decline and two showed negative NAPl / 027 DNA copy numbers. In Group 2, 1/6 mice showed a very low number of CD copies and five were negative. In Group 3, 2/6 animals were negative, one showed very low CD DNA, two showed moderate and one showed very high numbers of NAPl / 027 DNA copies. In Group 4, the cecal content of four mice showed between 2-4 numbers of NAPl / 027 log DNA copies. [0133] Figure 5 shows results of a histopathology investigation of cecum tissues obtained from the animals in the experiment. Figure 5A shows the histopathology of tissue from the cecum of animals in Group 1 (symbiotic group), Figure 5B; Group 2 caecum (probiotic group) (40 x view) reveals normal tubular glands and well-preserved superficial columnar epithelium. Figure 5C; Group 3 caecums (prebiotic group) have small areas with an irregular surface. Low numbers of polymorphs are visible between crypts on the lamina propria. Figure 5D; Group 4 caecum (control group) showing ulceration with suppression of lining of mucosal epithelial cells and crypts in the caecum. The mucosa and sub-mucosa are hemorrhagic and show severe inflammatory edema. [0134] Caecal samples from Groups 1-3 do not show any signs of inflammation, but in Group 4, three animals were sacrificed due to severe colitis (Figure 5). The cecum of an animal in Group 1 and one in Group 3 showed 3+ and 2+ scores of inflammation. None of the animals in Group 2 showed inflammation. All mice that showed inflammation of the cecum in Groups 1 and 4 also tested positive for toxin A or B, in Group 2 all mice tested negative for toxin (Table 10). Table 10. qPCR analyzes of the CD strain NAP1 / 027, histopathological scores and toxin values of the cecum contents of the four groups of mice. [0135] "Relative fluorescence values. Cutoff levels for the toxin test: negative <0.13, equivocation> 0.13 to 0.37, positive> 0.37 * na, not determined, animals were severely ill and died from infection. Cecal content could not be harvested. [0136] In conclusion, the administration of a symbiotic mixture containing four probiotic strains and GOS, IMOS and RS or a probiotic containing a multi-strain mixture conferred a protective effect in mice treated with antibiotics against CDI with the NAP1 / 027 strain. Together, feeding with a symbiotic or a mixture of probiotics protected the mice against CD infection, and partial protection was provided by equivalent prebiotic feeding. This is the first study on the prevention of ICD in a mouse model using a new concept of treatment with symbiotic and probiotic. Microbiotic restoration. [0137] The feeding effect of a symbiotic supplement containing the probiotic strains LAB LU 28, LAB LU 30, Bif LU 10 and Bif LU 30 with the prebiotics GOS, IMOS and RS was investigated in a mouse model C57 / BL / 6. The multiplication of probiotic mixtures in feces at different points after feeding and in the cecum at the end of the experiment was followed. [0138] Before feeding the probiotic mixture to the C57BL / 6 mouse model, the mice were treated with a mixture of antibiotics to undo the native LAB and bifidobacterial microflora as described above in the prevention experiment. The DNA copy numbers of total probiotic bifidobacteria, total lactobacilli, LAB LU 28, LAB LU 33, Bif LU 10 and Bif LU 30 in caecum of the symbiotic and control groups were determined by qPCR. Significance is expressed as * P <0.05 (Figure 6). [0139] In the symbiotic group, Total LAB and bifidobacteria increased after feeding the symbiotic mixture to mice treated with antibiotics compared to the control group. Total cecum bifidobacteria counts were higher in the symbiotic group than in the control group and cultivable bifidobacteria were not detected. The counts of total fecal bifidobacteria and Bif LU 10 increased during half of the symbiotic treatment, and at the end of the experiments. The DNA copies of faecal LAB LU 33, Bif LU 10 and Bif LU 30 were higher at the end of the experiment. [0140] Ceca of the symbiotic group showed the highest counts of bifidobacteria and LAB. LAB LU 28, LAB LU 33 and Bif LU 10 compared to the control group as determined by qPCR (Figure 6). There was no significant difference in the DNA copies of LAB between the symbiotic and control groups. The DNA copy numbers of BIF LU 30 were higher in the symbiotic group compared to the control group, but with no significant difference. Therefore, probiotic strains multiplied well in the presence of prebiotics and RS in the cecum of antibiotic-treated mice, such as Total LAB and bifidobacteria counts increased significantly in feces and cecum as determined by colony counts and qPCR. The fact that LAB LU 28, LAB LU 33, Bif LU 10 and Bif LU 30 were covered with fecal and caecal samples, can be concluded that the use of prebiotics in a symbiotic mixture, promoted the multiplication and colonization of the selected probiotic strains in the murine intestine. In the present composition of the four strains with GOS, IMOS and RS it was seen that the multiplication of each strain was in an equal proportion in the cecum. Security experiment [0141] The safety of the composition comprising LAB LU 28, LAB LU 33, Bif LU 10 and Bif LU 30 with GOS and RS has been established in an immunocompromised mouse model C57 / BL / 6. The mice were immunocompromised using methotrexate, a dihydrofolate reductase inhibitor and DNA synthesis is widely used in cancer chemotherapy. Methotrexate (3.5 mg / kg) was given orally to mice for three days. After two days, the symbiotic group was given 4x1010 cfu / ml with 5% GOS in water. RS was mixed with feed and given daily to mice for six days. On the 7th day, the mice were killed and the liver, spleen, blood and kidney were harvested by viability investigation using the liver and plaque counting method for histopathology. [0142] The results confirmed no translocation of bacteria to liver, blood, kidney, spleen and that histopathology of the liver was normal. In addition, it was found that white blood cell counts were reduced in the control group after treatment with methotrexate, and that feeding the symbiotic supplement for 7 days raised the WBC count level.
权利要求:
Claims (11) [0001] Symbiotic composition comprising at least two bacterial strains selected from the group consisting of the genera Lactobacillus and Bifidobacteria, and one or more prebiotic substances, characterized by the fact that - at least one of the bacterial strains is Bifidobacterium breve Bif LU 10 (deposit N ° LMG P-26117) and capable of degrading starch; and - at least one prebiotic substance is starch. [0002] Symbiotic composition according to claim 1, characterized by the fact that the starch is resistant starch (RS) and / or soluble starch (SS). [0003] Symbiotic composition according to any one of claims 1-2, characterized by the fact that one of said bacterial strains is a strain that does not degrade starch. [0004] Symbiotic composition according to claim 3, characterized by the fact that the bacterial strain that does not degrade starch is of the Lactobacillus paracasei species. [0005] Symbiotic composition according to claim 3, characterized by the fact that the bacterial strain that does not degrade starch is LAB LU 33 (deposit N ° LMG P-26118). [0006] Symbiotic composition according to any one of claims 1 to 5, characterized in that it also comprises one or more of the strains LAB LU 23 (deposit N ° LMG P-2 6119), LAB LU 28 (deposit N ° LMG P-26120 ), BIF LU 29 (deposit N ° LMG P-26115), and / or BIF LU 30 (deposit N ° LMG P-26116). [0007] Symbiotic composition according to claim 6, characterized by the fact that it comprises at least LAB LU 33 (deposit N ° LMG P-26118), and BIF LU 30 (deposit N ° LMG P-26116). [0008] Symbiotic composition according to claim 6, characterized by the fact that it comprises at least LAB LU 33 (deposit N ° LMG P-26118), BIF LU 30 (deposit N ° LMG P-26116), and LAB LU 28 (deposit N ° LMG P26120). [0009] Symbiotic composition according to any one of claims 1-8, characterized by the fact that one or more of the bacterial strains was exposed to acid, bile and / or mucin during their production. [0010] Symbiotic composition according to any one of claims 1-9, characterized in that it further comprises a prebiotic substance in the group consisting of disaccharides, oligosaccharides, and / or polysaccharides. [0011] Symbiotic composition according to any one of claims 1-10, characterized by the fact that it is for use in colonizing a subject's intestinal mucosa.
类似技术:
公开号 | 公开日 | 专利标题 BR112013020312B1|2021-03-23|SYMBOTIC COMPOSITIONS FOR RESTORATION AND RECONSTITUTION OF THE INTESTINAL MICROBIOTA AU2017226831B2|2018-10-04|Compositions comprising bacterial Blautia strains for treating visceral hypersensitivity US10967010B2|2021-04-06|Compositions comprising bacterial strains Macfarlane2010|Prebiotics in the gastrointestinal tract Kondepudi et al.2012|Prebiotic-non-digestible oligosaccharides preference of probiotic bifidobacteria and antimicrobial activity against Clostridium difficile Saadatzadeh et al.2013|Probiotic properties of lyophilized cell free extract of Lactobacillus casei Pande et al.2012|Prospectus of probiotics in modern age diseases WO2016060539A1|2016-04-21|Strains of lactobacillus brevis isolated from agave juice with bile salt hydrolase activity, and method for the isolation and selection thereof US11224620B2|2022-01-18|Compositions comprising bacterial strains Casanova2015|Development of an improved propionibacterium for potential use as a nutraceutical towards the prevention-treatment of colorectal cancer Balayan et al.2010|Some peculiarities of growth and functional activity of Escherichia coli strain from probiotic formula “ASAP” WO2021133812A1|2021-07-01|Compositions comprising microbes and methods of use and making thereof Yuan et al.2014|Microecology Intervention in Prevention and Treatment of Infectious Diseases
同族专利:
公开号 | 公开日 PL2672980T3|2018-05-30| JP2014506463A|2014-03-17| BR112013020312A2|2016-10-18| WO2012108830A1|2012-08-16| US8927252B2|2015-01-06| CN103491969A|2014-01-01| AP2013007097A0|2013-09-30| LT2672980T|2018-03-12| DK2672980T3|2018-02-26| EP2672980B1|2017-12-06| JP5905032B2|2016-04-20| US20130336931A1|2013-12-19| EP2672980A1|2013-12-18|
引用文献:
公开号 | 申请日 | 公开日 | 申请人 | 专利标题 CN1056750C|1993-12-10|2000-09-27|济南三株药业有限公司|Sanzhu oral liquid and its preparing method| AUPM823094A0|1994-09-16|1994-10-13|Goodman Fielder Limited|Probiotic compositions| AT407700T|1996-03-20|2008-09-15|Univ New South Wales|CHANGE OF MICROBENFLORA IN THE DIGESTIVE TRACT| DK0907735T5|1996-05-24|2010-06-14|Biogen Idec Inc|Tissue regeneration modulators| US6078284A|1996-09-30|2000-06-20|Qualcomm Incorporated|Passive position determination using two low-earth orbit satellites| EP0856259B1|1996-12-23|1998-08-12|SITIA-YOMO S.p.A.|Composition for feed use comprising lyophilized live lactic bacteria| CN1119154C|1998-01-20|2003-08-27|上海信谊药业有限公司|Live triple bifidobacteria preparation and preparing method thereof| JPH11302158A|1998-04-16|1999-11-02|Oruto Corporation:Kk|Health food having intestinal function controlling action and produced by using enteric seam capsule| JP2001097870A|1999-09-30|2001-04-10|Snow Brand Milk Prod Co Ltd|Method for absorption of bile acid using lactic acid bacterium| BR0109939A|2000-04-18|2003-05-27|Nestle Sa|Nutritional Modules| FI109602B|2001-01-25|2002-09-13|Valio Oy|Probiotkombination| SE0400355D0|2004-02-17|2004-02-17|Synbiotics Ab|New synbiotec use| JP2007082403A|2004-03-26|2007-04-05|Nippon Medicine:Kk|Food and drink containing complex composition comprising yucca extract, quillaia extract and lactobacillus, and method for producing the same| MY149913A|2006-03-07|2013-10-31|Nestec Sa|Synbiotic mixture| CA2689862A1|2006-06-09|2007-12-13|Nutravital Inc.|Probiotic compositions comprising propionibacterium and uses thereof| EP2251022A1|2009-05-11|2010-11-17|Nestec S.A.|Non-replicating micro-organisms and their immune boosting effect|GB201112091D0|2011-07-14|2011-08-31|Gt Biolog Ltd|Bacterial strains isolated from pigs| GB201117313D0|2011-10-07|2011-11-16|Gt Biolog Ltd|Bacterium for use in medicine| US8906668B2|2012-11-23|2014-12-09|Seres Health, Inc.|Synergistic bacterial compositions and methods of production and use thereof| CN104955466A|2012-11-23|2015-09-30|赛里斯治疗公司|Synergistic bacterial compositions and methods of production and use thereof| RU2015125519A|2012-11-29|2017-01-10|Нестек С.А.|SYNBIOTIC COMPOSITION AND ITS APPLICATION| US10973861B2|2013-02-04|2021-04-13|Seres Therapeutics, Inc.|Compositions and methods| CN110917220A|2013-02-04|2020-03-27|赛里斯治疗公司|Therapeutic compositions and methods of use thereof| JP2016519664A|2013-03-15|2016-07-07|セレス セラピューティクス インコーポレイテッド|Microbial composition and method based on network| GB201306536D0|2013-04-10|2013-05-22|Gt Biolog Ltd|Polypeptide and immune modulation| MX2016005303A|2013-10-25|2016-08-11|Nch Corp|Delivery system and probiotic composition for animals and plants.| WO2015077794A1|2013-11-25|2015-05-28|Seres Health, Inc.|Synergistic bacterial compositions and methods of production and use thereof| US9956282B2|2013-12-16|2018-05-01|Seres Therapeutics, Inc.|Bacterial compositions and methods of use thereof for treatment of immune system disorders| US10766799B2|2014-05-23|2020-09-08|Nch Corporation|Method for improving quality of aquaculture pond water using a nutrient germinant composition and spore incubation method| WO2015179788A1|2014-05-23|2015-11-26|Nch Corporation|Method for improving quality of aquaculture pond water| CN104171421A|2014-08-08|2014-12-03|河南牧翔动物药业有限公司|Feed additive for conditioning intestines of animals| JP6247185B2|2014-09-29|2017-12-13|森永乳業株式会社|Vylophila bacterium growth inhibitor and method for suppressing virulence bacteria growth| PT3193901T|2014-12-23|2018-06-29|4D Pharma Res Ltd|Pirin polypeptide and immune modulation| MA51639A|2015-06-15|2020-04-15|4D Pharma Res Ltd|COMPOSITIONS CONTAINING BACTERIAL STRAINS| SI3307288T1|2015-06-15|2019-11-29|4D Pharma Res Ltd|Compositions comprising bacterial strains| MA41010B1|2015-06-15|2020-01-31|4D Pharma Res Ltd|Compositions comprising bacterial strains| MA41060B1|2015-06-15|2019-11-29|4D Pharma Res Ltd|Compositions comprising bacterial strains| AU2016278072B2|2015-06-15|2020-07-23|4D Pharma Research Limited|Compositions comprising bacterial strains| ITUB20154965A1|2015-11-05|2017-05-05|Univ Degli Studi Di Camerino|EXTRACT OF LENTILS WITH HYPOCOLESTEROLEMIZING ACTION AND PREBIOTICS| GB201520497D0|2015-11-20|2016-01-06|4D Pharma Res Ltd|Compositions comprising bacterial strains| CN112569262A|2015-11-20|2021-03-30|4D制药研究有限公司|Compositions comprising bacterial strains| GB201520638D0|2015-11-23|2016-01-06|4D Pharma Res Ltd|Compositions comprising bacterial strains| GB201520631D0|2015-11-23|2016-01-06|4D Pharma Res Ltd|Compositions comprising bacterial strains| JP6441536B2|2016-03-04|2018-12-19|フォーディー ファーマ ピーエルシー４Ｄ Ｐｈａｒｍａ Ｐｌｃ|Composition comprising a bacterial strain| TW201821093A|2016-07-13|2018-06-16|英商４Ｄ製藥有限公司|Compositions comprising bacterial strains| GB201612191D0|2016-07-13|2016-08-24|4D Pharma Plc|Compositions comprising bacterial strains| EP3484311A1|2016-07-18|2019-05-22|Metagenics, Inc.|Compositions and methods for managing digestive disorders and a healthy microbiome| GB201621123D0|2016-12-12|2017-01-25|4D Pharma Plc|Compositions comprising bacterial strains| US20200085884A1|2016-12-15|2020-03-19|The Board Of Trustees Of The Leland Stanford Junior University|Compositions and methods for modulating growth of a genetically modified gut bacterial cell| JP2020520911A|2017-05-22|2020-07-16|フォーディー ファーマ リサーチ リミテッド４Ｄ Ｐｈａｒｍａ Ｒｅｓｅａｒｃｈ Ｌｉｍｉｔｅｄ|Composition comprising a bacterial strain| WO2018215782A1|2017-05-24|2018-11-29|4D Pharma Research Limited|Compositions comprising bacterial strain| WO2018229188A1|2017-06-14|2018-12-20|4D Pharma Research Limited|Compositions comprising bacterial strains| RS60910B1|2017-06-14|2020-11-30|4D Pharma Res Ltd|Compositions comprising a bacterial strain of the genus megasphaera and uses thereof| WO2019069266A1|2017-10-04|2019-04-11|Asian Institute Of Public Health|A pharmaceutical composition comprising a probiotic and a prebiotic to prevent acquisition of or treat drug resistant infections| US20200215127A1|2019-01-09|2020-07-09|LifeBidge Health, Inc.|Targeted synbiotic therapy for dysbiosis-related intestinal and extra-intestinal disorders| WO2021081362A1|2019-10-25|2021-04-29|Newgen 27, Llc|Synbiotic compositions for gut microbiota| KR102133802B1|2020-02-14|2020-07-14|이혜경|Meat snack composition for pet's health care and its manufacturing method| KR102139718B1|2020-02-25|2020-07-30|주식회사 항신바이탈|Animal feed additive composition containing beneficial bacteria and feed comprising the same| WO2021261626A1|2020-06-25|2021-12-30|주식회사 인실리코|Synbiotics composition for improving gut microbiota, comprising polysaccharide nanoparticles|
法律状态:
2017-10-24| B07D| Technical examination (opinion) related to article 229 of industrial property law| 2018-03-27| B15K| Others concerning applications: alteration of classification|Ipc: A61K 35/747 (2015.01), A23L 29/30 (2016.01), A23L | 2018-04-03| B06F| Objections, documents and/or translations needed after an examination request according art. 34 industrial property law| 2018-05-02| B07G| Grant request does not fulfill article 229-c lpi (prior consent of anvisa)| 2019-09-03| B06U| Preliminary requirement: requests with searches performed by other patent offices: suspension of the patent application procedure| 2020-04-07| B25A| Requested transfer of rights approved|Owner name: SYNBIOTICS AB (SE) | 2020-09-24| B06A| Notification to applicant to reply to the report for non-patentability or inadequacy of the application according art. 36 industrial patent law| 2021-01-12| B09A| Decision: intention to grant| 2021-03-23| B16A| Patent or certificate of addition of invention granted|Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 09/02/2012, OBSERVADAS AS CONDICOES LEGAIS. |
优先权:
[返回顶部]
申请号 | 申请日 | 专利标题 SE1100084-1|2011-02-09| SE1100084|2011-02-09| SE1100455|2011-06-13| SE1100455-3|2011-06-13| SE1100487-6|2011-06-21| SE1100487|2011-06-21| PCT/SE2012/050131|WO2012108830A1|2011-02-09|2012-02-09|Synbiotic compositions for restoration and reconstitution of gut microbiota| 相关专利
Sulfonates, polymers, resist compositions and patterning process
Washing machine
Washing machine
Device for fixture finishing and tension adjusting of membrane
Structure for Equipping Band in a Plane Cathode Ray Tube
Process for preparation of 7 alpha-carboxyl 9, 11-epoxy steroids and intermediates useful therein an
国家/地区
|